Streetbeat News

Price Targets

KDP

Jefferies analyst Kaumil Gajrawala has initiated coverage on Keurig Dr Pepper (NASDAQ:KDP) with a Buy rating and set a price target of $39. This new coverage could influence investor sentiment and potentially impact KDP's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 11:35 am

COCO

Jefferies analyst Kaumil Gajrawala has initiated coverage on Vita Coco (NASDAQ:COCO) with a Buy rating and set a price target of $33.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 11:34 am

SAM

Jefferies analyst Kaumil Gajrawala has initiated coverage on Boston Beer Co (NYSE:SAM) with a Hold rating and set a price target of $375 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 11:21 am

KO

Jefferies analyst Kaumil Gajrawala has initiated coverage on Coca-Cola (NYSE:KO) with a Hold rating and set a price target of $64.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 11:19 am

PG

Jefferies analyst Kaumil Gajrawala has initiated coverage on Procter & Gamble (NYSE:PG) with a Buy rating and set a price target of $177.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 11:17 am

NAPA

Jefferies analyst Kaumil Gajrawala has initiated coverage on Duckhorn Portfolio (NYSE:NAPA) with a Buy rating and set a price target of $13 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 11:15 am

MNST

Jefferies analyst Kaumil Gajrawala has initiated coverage on Monster Beverage (NASDAQ:MNST) with a Buy rating and set a price target of $65.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 11:13 am

CLX

Jefferies analyst Kaumil Gajrawala has initiated coverage on Clorox (NYSE:CLX) with an Underperform rating and set a price target of $117.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 11:08 am

MICS

Ascendiant Capital analyst Edward Woo has initiated coverage on Singing Machine Co (NASDAQ:MICS) with a Buy rating and set a price target of $4.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 11:06 am

MIRM

Morgan Stanley analyst Michael Ulz has initiated coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with an Overweight rating and set a price target of $60.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 11:05 am